Prahsant Kumar The commercialization landscape for cell and gene therapies (CGT) has historically been restricted by rigid regulatory frameworks designed for traditional biologics. Moving a highly volatile, patient-specific autologous therapy or a low-volume orphan gene vector through a conventional Biologics License Application (BLA) path often felt like forcing a square peg into a round hole. However, the FDA’s May … Read more
In the high-stakes world of drug development, traditional standalone clinical trials increasingly feel like running a marathon in heavy boots. Between soaring costs, competitive recruitment landscapes, and the urgent needs of patients, sponsors are desperately seeking more agile ways to innovate. Enter the FDA’s revised draft guidance on Master Protocols, a regulatory milestone designed to turn multi-study complexity into … Read more
In the high-stakes arena of medical device clearance, a single compromised data point can dismantle years of costly research and development. Recent FDA alerts targeting third-party testing laboratories in China have sent shockwaves through the global medtech industry, revealing widespread fabrication of critical performance data. While it is tempting to view these external laboratories as … Read more
The FDA’s newly minted June 2026 guidance, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products, reads like a regulatory dream. It outlines a world where a single, stellar trial paired with smart confirmatory evidence can win an approval. But experienced sponsors know that what is penned by leadership at the top of the agency often … Read more
Imagine spending years poured over a breakthrough biological drug, only to have its regulatory approval stalled by a messy spreadsheet. It is a heartbreak that happens far too often in drug development, where life-saving science clashes with rigid data infrastructure. For years, the path to proving a therapeutic protein won’t trigger an unintended immune response in patients has been … Read more
The world of medical innovation moves at a breathtaking pace, yet getting life-saving therapies to the people who need them requires a complex dance between developers and insurers. Healthcare payors and formulary committees have the monumental task of evaluating a continuous stream of clinical data to decide which treatments are covered and at what cost. … Read more
Every morning, millions of us strap on a smartwatch or slip on a smart ring, silently tracking our heart rates, sleep cycles, and daily step counts. We eagerly hand this intimate biological data over to massive tech conglomerates, watching our trends update in beautiful, gamified interfaces. Yet, an intriguing psychological paradox emerges the second we step into … Read more
The modern regulatory landscape is a complex battlefield where the demand for rapid medical innovation constantly clashes with the absolute necessity for scientific certainty. For years, public health experts, clinical trialists, and consumer advocates have engaged in a fierce debate over the wisdom of expedited approval pathways. Critics argue that shortened regulatory timelines systematically compromise … Read more
The landscape of pharmaceutical manufacturing is undergoing a profound paradigm shift, moving away from reactive compliance and toward predictive, science-based quality ecosystems. For GMP executives, staying ahead of this evolution requires more than just tracking regulatory changes; it demands a deep understanding of how global harmonization shapes shop-floor reality. The FDA’s recently updated guidance, “Q8, … Read more
If you are running a life science company today, you already know that the traditional path of running massive clinical trials for every single answer is burning through your runway too fast. The good news is that the FDA’s formal adoption of the global ICH M15 framework means regulators are finally ready to let smart … Read more
